| Original language | English (US) |
|---|---|
| Pages (from-to) | e211-e212 |
| Journal | Biology of Blood and Marrow Transplantation |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2019 |
ASJC Scopus subject areas
- Hematology
- Transplantation
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 6, 06.2019, p. e211-e212.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply
AU - Lee, Daniel W.
AU - Mead, Elena
AU - Santomasso, Bianca D.
AU - Turtle, Cameron J.
AU - Grupp, Stephan A.
AU - Neelapu, Sattva S.
N1 - Funding Information: Conflict of interest statement: D.W.L. has received clinical trial support from Kite/Gilead and serves as a consultant and advisory board member for Juno Therapeutics/ Celgene . B.D.S. has consulted or participated in advisory boards for Juno Therapeutics/Celgene, Kite Pharma/Gilead, and Novartis. C.J.T. has received research support from Juno Therapeutics and Nektar Therapeutics; has consulted or participated in advisory boards for Juno Therapeutics/Celgene, Nektar Therapeutics, Precision Biosciences, Eureka Therapeutics, Aptevo, Gilead, and Caribou Biosciences; and has option grants in Precision Biosciences, Eureka Therapeutics, and Caribou Biosciences. S.A.G. has received research and/or clinical trial support from Novartis , Servier and Kite. Consulting, study steering committees, or scientific advisory boards: Novartis , Adaptimmune, Eureka, TCR2, Juno, GlaxoSmithKline , Cellectis, Vertex, Cure Genetics, and Roche. S.S.N. has received research support from Kite/Gilead, Celgene , Cellectis, Poseida, Merck , Acerta, Karus, and BMS; served as consultant and advisory board member for Kite/Gilead, Celgene, Novartis, Unum Therapeutics, Pfizer, and Merck. Funding Information: Financial disclosure:, Conflict of interest statement: D.W.L. has received clinical trial support from Kite/Gilead and serves as a consultant and advisory board member for Juno Therapeutics/Celgene. B.D.S. has consulted or participated in advisory boards for Juno Therapeutics/Celgene, Kite Pharma/Gilead, and Novartis. C.J.T. has received research support from Juno Therapeutics and Nektar Therapeutics; has consulted or participated in advisory boards for Juno Therapeutics/Celgene, Nektar Therapeutics, Precision Biosciences, Eureka Therapeutics, Aptevo, Gilead, and Caribou Biosciences; and has option grants in Precision Biosciences, Eureka Therapeutics, and Caribou Biosciences. S.A.G. has received research and/or clinical trial support from Novartis, Servier and Kite. Consulting, study steering committees, or scientific advisory boards: Novartis, Adaptimmune, Eureka, TCR2, Juno, GlaxoSmithKline, Cellectis, Vertex, Cure Genetics, and Roche. S.S.N. has received research support from Kite/Gilead, Celgene, Cellectis, Poseida, Merck, Acerta, Karus, and BMS; served as consultant and advisory board member for Kite/Gilead, Celgene, Novartis, Unum Therapeutics, Pfizer, and Merck. Financial disclosure: See Acknowledgments on page e211
PY - 2019/6
Y1 - 2019/6
UR - http://www.scopus.com/inward/record.url?scp=85066844566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066844566&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2019.03.019
DO - 10.1016/j.bbmt.2019.03.019
M3 - Letter
C2 - 30910604
AN - SCOPUS:85066844566
SN - 1083-8791
VL - 25
SP - e211-e212
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 6
ER -